Immunic Inc
IMUX
Market Cap$145.03M
Close$
$0.35
65.7% downside
Current Fair Value
65.7% downsideOvervalued by 65.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $145.03 Million |
|---|---|
| Enterprise Value | $110.36 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.11 |
| Beta | 1.84 |
| Outstanding Shares | 101,272,580 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.71 |
|---|---|
| PEG | -24.36 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.15 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Immunic Inc
28 employees
CEO: Daniel Vitt Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerati...